Literature DB >> 17534444

Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice.

Therese Seierstad1, Sigurd Folkvord, Kathrine Røe, Kjersti Flatmark, Arne Skretting, Dag Rune Olsen.   

Abstract

PURPOSE: The purpose of this study was to evaluate the possible use of changes in apparent diffusion coefficient (ADC) measured by magnetic resonance imaging for pretreatment prediction and early detection of tumor response in a mouse model during fractionated chemoradiotherapy.
MATERIALS AND METHODS: Athymic mice with bilateral HT29 xenografts on rear flanks were allocated into three groups: control, capecitabine, and capecitabine and oxaliplatin. The left flanks of the mice received daily irradiation. T2 and diffusion images were acquired before therapy and weekly for the following 9 weeks. Pretreatment and changes in ADC were calculated and compared with tumor doubling growth delay.
RESULTS: No correlations between pretreatment ADC and changes in tumor volumes after therapy were seen. All treated tumors, except those receiving capecitabine (P = .06), showed increased mean tumor ADC values 11 days after initialization of therapy (P < .05) before returning to pretreatment values within 5 days posttherapy (day 18 after onset of therapy). This increase in mean tumor ADC showed a strong positive correlation (r = 0.92, P < .01) with mean tumor doubling growth delay.
CONCLUSIONS: Pretreatment ADC values did not predict the effectiveness of therapy, whereas early changes in mean ADC quantitatively correlated with treatment outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17534444      PMCID: PMC1877980          DOI: 10.1593/neo.07154

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  43 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

Review 3.  Applications of magnetic resonance in model systems: tumor biology and physiology.

Authors:  R J Gillies; Z M Bhujwalla; J Evelhoch; M Garwood; M Neeman; S P Robinson; C H Sotak; B Van Der Sanden
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 4.  Applications of magnetic resonance in model systems: cancer therapeutics.

Authors:  J L Evelhoch; R J Gillies; G S Karczmar; J A Koutcher; R J Maxwell; O Nalcioglu; N Raghunand; S M Ronen; B D Ross; H M Swartz
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

5.  Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging.

Authors:  J P Galons; M I Altbach; G D Paine-Murrieta; C W Taylor; R J Gillies
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

6.  A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.

Authors:  Marwan G Fakih; Ashwani Rajput; Gary Y Yang; Lakshmi Pendyala; Karoly Toth; Judy L Smith; David D Lawrence; Youcef M Rustum
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-05       Impact factor: 7.038

Review 7.  Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy.

Authors:  Risto A Kauppinen
Journal:  NMR Biomed       Date:  2002-02       Impact factor: 4.044

8.  X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.

Authors:  N Sawada; T Ishikawa; F Sekiguchi; Y Tanaka; H Ishitsuka
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

9.  Radiosensitization by oxaliplatin in a mouse adenocarcinoma: influence of treatment schedule.

Authors:  Anna Cividalli; Francesca Ceciarelli; Esther Livdi; Pierluigi Altavista; Giorgio Cruciani; Paolo Marchetti; Donatella Tirindelli Danesi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-15       Impact factor: 7.038

10.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.

Authors:  T L Chenevert; L D Stegman; J M Taylor; P L Robertson; H S Greenberg; A Rehemtulla; B D Ross
Journal:  J Natl Cancer Inst       Date:  2000-12-20       Impact factor: 13.506

View more
  18 in total

1.  Earlier detection of tumor treatment response using magnetic resonance diffusion imaging with oscillating gradients.

Authors:  Daniel C Colvin; Mary E Loveless; Mark D Does; Zou Yue; Thomas E Yankeelov; John C Gore
Journal:  Magn Reson Imaging       Date:  2010-12-28       Impact factor: 2.546

2.  Combined value of apparent diffusion coefficient-standardized uptake value max in evaluation of post-treated locally advanced rectal cancer.

Authors:  Davide Ippolito; Davide Fior; Chiara Trattenero; Elena De Ponti; Silvia Drago; Luca Guerra; Cammillo Talei Franzesi; Sandro Sironi
Journal:  World J Radiol       Date:  2015-12-28

3.  Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma.

Authors:  Yi-lei Zhao; Qing-qu Guo; Gen-ren Yang; Qi-dong Wang
Journal:  J Zhejiang Univ Sci B       Date:  2014-08       Impact factor: 3.066

4.  Assessment of multiexponential diffusion features as MRI cancer therapy response metrics.

Authors:  Benjamin A Hoff; Thomas L Chenevert; Mahaveer S Bhojani; Thomas C Kwee; Alnawaz Rehemtulla; Denis Le Bihan; Brian D Ross; Craig J Galbán
Journal:  Magn Reson Med       Date:  2010-09-21       Impact factor: 4.668

5.  On the relationship between the apparent diffusion coefficient and extravascular extracellular volume fraction in human breast cancer.

Authors:  Lori R Arlinghaus; Xia Li; A Ridwan Rahman; E Brian Welch; Lei Xu; John C Gore; Thomas E Yankeelov
Journal:  Magn Reson Imaging       Date:  2011-04-29       Impact factor: 2.546

6.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

7.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

8.  A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy.

Authors:  Craig J Galbán; Suresh K Mukherji; Thomas L Chenevert; Charles R Meyer; Daniel A Hamstra; Peyton H Bland; Timothy D Johnson; Bradford A Moffat; Alnawaz Rehemtulla; Avraham Eisbruch; Brian D Ross
Journal:  Transl Oncol       Date:  2009-08-18       Impact factor: 4.243

9.  Effect of b value on monitoring therapeutic response by diffusion-weighted imaging.

Authors:  Zhao-Xia Jiang; Wei-Jun Peng; Wen-Tao Li; Feng Tang; Shi-Yuan Liu; Xu-Dong Qu; Jian-Hua Wang; Hong-Feng Lu
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

10.  Early changes in the apparent diffusion coefficient and MMP-9 expression of a cervical carcinoma U14 allograft model following irradiation.

Authors:  Yecai Huang; Jianming Huang; Mei Feng; Jing Ren; Kun Mi; Jia Cheng; Bing Song; Jinyi Lang
Journal:  Oncol Lett       Date:  2017-09-22       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.